GSK's BCMA-directed antibody-drug conjugate Blenrep reduced the risk of death by 42% in a multiple myeloma trial that the company believes could be practice-changing. The DREAMM-7 study showed ...

However, in November 2022, Blenrep was withdrawn from the U.S. market after the failure of GSK’s phase III confirmatory study, DREAMM-3, which evaluated Blenrep in patients with relapsed or ...

While Blenrep has been granted accelerated approval by the FDA for multiple myeloma patients who have received at least four prior therapies – including an anti-CD38 monoclonal antibody, a ...

The latest increase reflects the revival of the once-withdrawn antibody-drug conjugate Blenrep, as well as “multiple launch opportunities in the ’26-to-’31 period,” GSK CEO Emma Walmsley ...

UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

Blenrep and depemokimab are expected to launch in 2025, with Blenrep's FDA PDUFA date set for July. Chief Financial Officer Julie Brown noted, "Core operating margin improved to 29.2%, up 130 ...

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.Most Read from BloombergState Farm Seeks Emergency Californ ...

This year, GSK expects five product approvals, including the relaunch of blood cancer drug Blenrep, which it estimates could eventually reach annual sales of more than 3 billion pounds.

It also faces competition from Pfizer and Moderna. Still, the drugmaker is optimistic about its prospects for the potential re-launch of its blood cancer drug Blenrep this year. Following positive ...

The company cited advances in its research and development pipeline, including plans for additional uses of its cancer drug Blenrep.

For 2025, GSK expects further growth in sales and core earnings, supported by plans to launch five medicines, including a comeback of previously withdrawn multiple myeloma treatment Blenrep.